Breast cancer, regarded as the “killer of beauty,” is a malignant tumor that severely threatens women’s health, with an increasing incidence year by year. Antibody-drug conjugates (ADC), as a new type of therapeutic drug, have become a hot research topic in the field of breast cancer due to their advantages of “high efficacy and low … Read more
By | Little Medicine Monster Global ADC Pipeline Status As of December 6, 2023, a total of 1166 ADC pipelines have been developed globally, with 524 pipelines under research and 16 approved drugs (including two TDM-1 biosimilars). The abandonment rate of pipelines is as high as 54% (1166-524-16/1166). Among the 524 pipelines under research, over … Read more
Focused and dedicated, stepping onto the international stage Written by|Little Medicine Monster The latest generation of anti-HER-2 ADC drug developed by Hengrui, SHR-A1811, is often jokingly referred to as the domestic alternative to DS-8201 due to its similar structure. However, strength will eliminate all rumors. Results from early clinical studies released by AACR this year … Read more
With DS8201 continuously dominating the field of HER-2 solid tumors such as breast cancer, gastric cancer, and lung cancer, the pressure on other HER2-ADCs is increasing day by day. Faced with a suddenly strong competitor, various HER2-ADC manufacturers have their own responses; some choose to join forces when they cannot compete, quickly following in the … Read more
Currently, 15 ADC drugs have been approved globally, of which 6 are approved in China, namely Enfortumab vedotin, Brentuximab vedotin, Trastuzumab deruxtecan, Gemtuzumab ozogamicin, Sacituzumab govitecan, and Loncastuximab tesirine. This article provides a brief summary of the currently approved ADC drugs, the types of tumors they are suitable for, and how to use them. 1. … Read more